NCoA-3 Antibody (AX 15): sc-56856
- NCoA-3 Antibody (AX 15) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 605-1294 of NCoA-3 of human origin
- recommended for detection of NCoA-3 of human origin by WB, IP, IF and IHC(P)
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for NCoA-3 Antibody (AX 15) for WB and IHC(P) applications. These reagents are now offered in bundles with NCoA-3 Antibody (AX 15) (see ordering information below).
NCoA-3 Antibody (AX 15) is a mouse monoclonal IgG1 antibody that detects NCoA-3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). NCoA-3, also known as RAC3, ACTR, AIB-1, and p/CIP, plays a crucial role as a transcriptional coactivator that interacts with steroid hormone receptors, thereby influencing gene expression in response to hormonal signals. NCoA-3 is particularly significant in cancer biology, showing overexpression in estrogen receptor-positive ovarian and breast cancers, where NCoA-3 is essential for the transcriptional activation of p300/CBP-dependent transcription factors. NCoA-3′s ability to modulate transcriptional activity highlights NCoA-3′s importance in regulating genes involved in cell proliferation and survival, making NCoA-3 a key player in the development and progression of hormone-responsive tumors. Anti-NCoA-3 antibody (AX 15) enables researchers to gain valuable insights into hormone action mechanisms and coactivator roles in cancer, facilitating the exploration of potential therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
NCoA-3 Antibody (AX 15) References:
- Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. | Zhao, C., et al. 2003. Cancer. 98: 18-23. PMID: 12833450
- The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6. | Arimura, A., et al. 2004. J Biol Chem. 279: 31105-12. PMID: 15145939
- Polyglutamine repeat length in the NCOA3 does not affect risk in familial breast cancer. | Wilkening, S., et al. 2005. Cancer Epidemiol Biomarkers Prev. 14: 291-2. PMID: 15668512
- NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. | Esteyries, S., et al. 2008. Leukemia. 22: 663-5. PMID: 17805331
- Investigation of the 1758G>C and 2880A>G variants within the NCOA3 gene in a breast cancer affected Australian population. | Gabrovska, PN., et al. 2011. Gene. 482: 68-72. PMID: 21601620
- Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. | Burandt, E., et al. 2013. Breast Cancer Res Treat. 137: 745-53. PMID: 23322234
- Esrrb directly binds to Gata6 promoter and regulates its expression with Dax1 and Ncoa3. | Uranishi, K., et al. 2016. Biochem Biophys Res Commun. 478: 1720-5. PMID: 27601327
- Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. | Kundu, S., et al. 2018. Genome Med. 10: 2. PMID: 29301589
- Genome-wide analysis of thyroid function in Australian adolescents highlights SERPINA7 and NCOA3. | Nolan, J., et al. 2021. Eur J Endocrinol. 185: 743-753. PMID: 34524976
- Clinicopathologic and genetic characterization of angiofibroma of soft tissue: a study of 12 cases including two cases with AHRR::NCOA3 gene fusion. | Yamashita, K., et al. 2023. Histopathology. 83: 57-66. PMID: 36860189
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NCoA-3 Antibody (AX 15) | sc-56856 | 200 µg/ml | $322.00 | |||
NCoA-3 Antibody (AX 15): m-IgG Fc BP-HRP Bundle | sc-537126 | 200 µg Ab; 10 µg BP | $361.00 | |||
NCoA-3 Antibody (AX 15): m-IgGκ BP-HRP Bundle | sc-534318 | 200 µg Ab; 40 µg BP | $361.00 |